Evaluation of Anti-Mullerian Hormone in Predicting In Vitro Fertilization Cycle Outcomes

Abstract

Aim: This study was conducted to explore the effect of serum anti-Mullerian hormone (AMH) level on in vitro fertilization (IVF) cycle outcomes. Material and Methods: A total of 142 patients included in this study, were divided into three groups according to their serum AMH levels as Group 1: AMH level 5-10 ng/ml (n=108), Group 2: AMH level 10-15 ng/ml (n=20), and Group 3: AMH level >15 ng/ml (n=14). Demographic characteristics were recorded. The duration of infertility and stimulation, the number of cycles, initial, final, and total doses of gonadotropins, and estradiol (E2) and progesterone levels on the day of trigger, oocyte pick up (OPU) and embryo transfer (ET), the total number of oocytes retrieved, the number of mature oocytes, the number and quality of the embryo, and also endometrial thickness on the day of trigger, OPU and ET, the distance of embryo-fundus, the day of ET, and pregnancy outcomes were all recorded. Results: While the IVF treatment indications and pregnancy outcomes were similar between the groups, body mass index (BMI) was significantly higher in Group 2 and Group 3 than in Group 1 (p<0.001). The total doses of gonadotropin were significantly higher in Group 2 than in Group 1 and Group 3, and the total oocyte count was also significantly higher in Group 3 than in Group 1 (p=0.006, and p=0.015, respectively) Conclusion: AMH levels were associated with BMI and total oocyte count, but not with mature oocyte count, oocyte quality, and pregnancy outcomes.